A microRNA biomarker panel for the non-invasive detection of bladder cancer.
| Autor: | Urquidi V; Nonagen Bioscience Corporation, Jacksonville, FL, USA., Netherton M; Cancer Research Institute, MD Anderson Cancer Center, Orlando, FL, USA., Gomes-Giacoia E; Cancer Research Institute, MD Anderson Cancer Center, Orlando, FL, USA., Serie DJ; Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL USA., Eckel-Passow J; Department of Health Sciences Research, Mayo Clinic, Rochester, MN USA., Rosser CJ; Nonagen Bioscience Corporation, Jacksonville, FL, USA.; University of Hawaii Cancer Center, Honolulu, HI USA., Goodison S; Nonagen Bioscience Corporation, Jacksonville, FL, USA.; Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL USA.; Department of Urology, Mayo Clinic, Jacksonville, FL USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Oncotarget [Oncotarget] 2016 Dec 27; Vol. 7 (52), pp. 86290-86299. |
| DOI: | 10.18632/oncotarget.13382 |
| Abstrakt: | The development of accurate, non-invasive urinary assays for bladder cancer would greatly facilitate the detection and management of a disease that has a high rate of recurrence and progression. In this study, we employed a discovery and validation strategy to identify microRNA signatures that can perform as a non-invasive bladder cancer diagnostic assay. Expression profiling of 754 human microRNAs (TaqMan low density arrays) was performed on naturally voided urine samples from a cohort of 85 subjects of known bladder disease status (27 with active BCa). A panel of 46 microRNAs significantly associated with bladder cancer were subsequently monitored in an independent cohort of 121 subjects (61 with active BCa) using quantitative real-time PCR (RT-PCR). Multivariable modeling identified a 25-target diagnostic signature that predicted the presence of BCa with an estimated sensitivity of 87% at a specificity of 100% (AUC 0.982). With additional validation, the monitoring of a urinary microRNA biomarker panel could facilitate the non-invasive evaluation of patients under investigation for BCa. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|